i) References
- World Health Organisation.
Onchocerciasis (river blindness) - Disease Information
https://www.who.int/blindness/partnerships/onchocerciasis_disease_information/en/
consulted on 14 April 2020.
- Kuesel AC. Research for new
drugs for elimination of onchocerciasis in Africa. Int J Parasitol
Drugs Drug Resist. 2016 May 19. pii: S2211-3207(16)30015-X.
doi:10.1016/j.ijpddr.2016.04.002
- Taylor MJ, Hoerauf A, Bockarie
M. Lymphatic filariasis and onchocerciasis. Lancet. 2010 Oct
2;376(9747):1175-85. doi:10.1016/S0140-6736(10)60586-7. Epub 2010 Aug
23.
- Bah GS, Tanya VN, Makepeace BL.
Immunotherapy with mutated onchocystatin fails to enhance the efficacy
of a sub-lethal oxytetracycline regimen against Onchocerca ochengi.
Vet Parasitol. 2015 Aug 15;212(1-2):25-34.
doi:10.1016/j.vetpar.2015.06.005. Epub 2015 Jun 12.
- Opoku NO, Bakajika DK, Kanza EM,
et al. Single dose moxidectin versus ivermectin for Onchocerca
volvulus infection in Ghana, Liberia, and the Democratic Republic of
the Congo: a randomised, controlled, double-blind phase 3 trial.
Lancet. 2018;392(10154):1207-1216.
- Pleiss U, Harder A, Turberg A,
Londershausen M, Iinuma K, Mencke N, Jeschke P, Bonse G. Synthesis of
a radiolabeled cyclodepsipeptide [3H-methyl] PF1022A. J Labelled
Comp Radiopharm. 1996;38:61-9.
- Omura S, Crump A. The life and
times of ivermectin—a success story. Nat Rev Microbiol
2004;2:984–989.
- Cotreau MM, et al. The
antiparasitic moxidectin: Safety, tolerability, and pharmacokinetics
in humans. J Clin Pharmacol 2003;43:1108–1115
- von Samson-Himmelstjerna G,
Harder A, Sangster NC, Coles GC. Efficacy of two
cyclooctadepsipeptides, PF1022A and emodepside, against
anthelmintic-resistant nematodes in sheep and cattle. Parasitol.
2005;130:343-7.
- Geary TG, Woo K, McCarthy JS,
Mackenzie CD, Horton J, Prichard RK, de Silva NR, Olliaro PL,
Lazdins-Helds JK, Engels DA, Bundy DA. Unresolved issues in
anthelmintic pharmacology for helminthiases of humans. Int J
Parasitol. 2010 Jan;40(1):1-13. doi: 10.1016/j.ijpara.2009.11.001.
- Zahner H et al. Filaricidal
efficacy of anthelmintically active cyclodepsipeptides. International
Journal for Parasitology. 2001;31:1515-1522.
- Zahner H et al. Effects of Bay
44-4400, a new cyclodepsipeptide, on developing stages of filariae
(Acanthocheilonema viteae, Brugia malayi, Litomosoides
sigmodontis ) in the rodent Mastomys coucha. Acta Tropica 2001 Sep
1;80(1).
- Drugs for Neglected Diseasesinitiative . Investigator Brochure Emopdepside - BAY 44-4400.
Version 3 dated 8 September 2017.
- Committee for Medicinal Products
for Human Use (CHMP). Guideline on strategies to identify and mitigate
risks for first-in-human and early clinical trials with
investigational medicinal products. EMEA/CHMP/SWP/28367/07 Rev. 1. 20
July 2017.
Data available on request from the authors.